Onychomycosis (Tinea Unguium)-Pipeline Review, H2 2015

Onychomycosis (Tinea Unguium)-Pipeline Review, H2 2015


  • Products Id :- GMDHC6868IDB
  • |
  • Pages: 68
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Onychomycosis (Tinea Unguium)-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Onychomycosis (Tinea Unguium)-Pipeline Review, H2 2015', provides an overview of the Onychomycosis (Tinea Unguium)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Onychomycosis (Tinea Unguium) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Onychomycosis (Tinea Unguium) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Onychomycosis (Tinea Unguium) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Onychomycosis (Tinea Unguium)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Onychomycosis (Tinea Unguium) Overview 8

Therapeutics Development 9

Pipeline Products for Onychomycosis (Tinea Unguium)-Overview 9

Pipeline Products for Onychomycosis (Tinea Unguium)-Comparative Analysis 10

Onychomycosis (Tinea Unguium)-Therapeutics under Development by Companies 11

Onychomycosis (Tinea Unguium)-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Unknown Stage Products 14

Onychomycosis (Tinea Unguium)-Products under Development by Companies 15

Onychomycosis (Tinea Unguium)-Companies Involved in Therapeutics Development 16

Anacor Pharmaceuticals, Inc. 16

Eisai Co., Ltd. 17

Helix BioMedix, Inc. 18

Hexima Limited 19

Meiji Seika Pharma Co., Ltd. 20

Moberg Pharma AB 21

NAL Pharmaceuticals Ltd. 22

Nihon Nohyaku Co., Ltd. 23

Novabiotics Limited 24

Nuvo Research Inc. 25

Viamet Pharmaceuticals, Inc. 26

Onychomycosis (Tinea Unguium)-Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

AN-2718-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

E-1224-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

ELS-160-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

HB-1275-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

HXP-124-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

luliconazole-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

ME-1111-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

NAL-3216-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

NP-213-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

terbinafine-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

terbinafine-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

VT-1161-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Onychomycosis (Tinea Unguium)-Recent Pipeline Updates 53

Onychomycosis (Tinea Unguium)-Dormant Projects 58

Onychomycosis (Tinea Unguium)-Discontinued Products 61

Onychomycosis (Tinea Unguium)-Product Development Milestones 62

Featured News & Press Releases 62

Mar 26, 2015: Moberg Pharma Announces Grant of EU Patent for MOB-015 Related to Topical Treatment of Onychomycosis (Nail Fungus) 62

Mar 13, 2015: MOB-015 Data To Be Presented At The 73rd Annual Meeting Of The American Academy Of Dermatology 62

Mar 10, 2015: Viamet Announces Initiation of RENOVATE Phase 2b Study of Oral VT-1161 in Onychomycosis 62

Feb 11, 2015: Moberg Pharma Announces Issue of U.S. Patent Related to MOB-015 for the Treatment of Onychomycosis 63

Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis 64

Sep 10, 2014: Data for Viamet's VT-1161 Presented at ICAAC 2014 64

Dec 13, 2013: Moberg Pharma reports positive interim results in phase II clinical study of MOB-015 65

May 27, 2013: Moberg Pharma Completes Enrollment In Phase II Clinical Trial Of MOB-015 65

Nov 07, 2012: Moberg Derma Initiates Phase II Trial With MOB-015 For Treatment Of Onychomycosis 66

Feb 14, 2012: NovaBiotics Receives US Patent Further Strengthening Novexatin 66

Appendix 67

Methodology 67

Coverage 67

Secondary Research 67

Primary Research 67

Expert Panel Validation 67

Contact Us 67

Disclaimer 68

List of Tables

Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2015 9

Number of Products under Development for Onychomycosis (Tinea Unguium)-Comparative Analysis, H2 2015 10

Number of Products under Development by Companies, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Development, H2 2015 13

Comparative Analysis by Unknown Stage Development, H2 2015 14

Products under Development by Companies, H2 2015 15

Onychomycosis (Tinea Unguium)-Pipeline by Anacor Pharmaceuticals, Inc., H2 2015 16

Onychomycosis (Tinea Unguium)-Pipeline by Eisai Co., Ltd., H2 2015 17

Onychomycosis (Tinea Unguium)-Pipeline by Helix BioMedix, Inc., H2 2015 18

Onychomycosis (Tinea Unguium)-Pipeline by Hexima Limited, H2 2015 19

Onychomycosis (Tinea Unguium)-Pipeline by Meiji Seika Pharma Co., Ltd., H2 2015 20

Onychomycosis (Tinea Unguium)-Pipeline by Moberg Pharma AB, H2 2015 21

Onychomycosis (Tinea Unguium)-Pipeline by NAL Pharmaceuticals Ltd., H2 2015 22

Onychomycosis (Tinea Unguium)-Pipeline by Nihon Nohyaku Co., Ltd., H2 2015 23

Onychomycosis (Tinea Unguium)-Pipeline by Novabiotics Limited, H2 2015 24

Onychomycosis (Tinea Unguium)-Pipeline by Nuvo Research Inc., H2 2015 25

Onychomycosis (Tinea Unguium)-Pipeline by Viamet Pharmaceuticals, Inc., H2 2015 26

Assessment by Monotherapy Products, H2 2015 27

Number of Products by Stage and Target, H2 2015 29

Number of Products by Stage and Mechanism of Action, H2 2015 31

Number of Products by Stage and Route of Administration, H2 2015 33

Number of Products by Stage and Molecule Type, H2 2015 35

Onychomycosis (Tinea Unguium) Therapeutics-Recent Pipeline Updates, H2 2015 53

Onychomycosis (Tinea Unguium)-Dormant Projects, H2 2015 58

Onychomycosis (Tinea Unguium)-Dormant Projects (Contd..1), H2 2015 59

Onychomycosis (Tinea Unguium)-Dormant Projects (Contd..2), H2 2015 60

Onychomycosis (Tinea Unguium)-Discontinued Products, H2 2015 61

List of Figures

Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2015 9

Number of Products under Development for Onychomycosis (Tinea Unguium)-Comparative Analysis, H2 2015 10

Number of Products under Development by Companies, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Products, H2 2015 13

Assessment by Monotherapy Products, H2 2015 27

Number of Products by Top 10 Targets, H2 2015 28

Number of Products by Stage and Top 10 Targets, H2 2015 28

Number of Products by Top 10 Mechanism of Actions, H2 2015 30

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 30

Number of Products by Top 10 Routes of Administration, H2 2015 32

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 32

Number of Products by Top 10 Molecule Types, H2 2015 34

Number of Products by Stage and Top 10 Molecule Types, H2 2015 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Anacor Pharmaceuticals, Inc.

Eisai Co., Ltd.

Helix BioMedix, Inc.

Hexima Limited

Meiji Seika Pharma Co., Ltd.

Moberg Pharma AB

NAL Pharmaceuticals Ltd.

Nihon Nohyaku Co., Ltd.

Novabiotics Limited

Nuvo Research Inc.

Viamet Pharmaceuticals, Inc.

Onychomycosis (Tinea Unguium) Therapeutic Products under Development, Key Players in Onychomycosis (Tinea Unguium) Therapeutics, Onychomycosis (Tinea Unguium) Pipeline Overview, Onychomycosis (Tinea Unguium) Pipeline, Onychomycosis (Tinea Unguium) Pipeline Assessment

select a license

Single User License
USD 2000 INR 128160
Site License
USD 4000 INR 256320
Corporate User License
USD 6000 INR 384480

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com